Due to the pivotal role of estrogens in normal breast proliferation and the identification of increased ERα expression as a risk factor for breast cancer development, preventive therapy is aimed at reducing estrogen levels and/or antagonizing receptor activity. Here, ESR1 is linked to breast carcinoma.